Bimagrumab Bimagrumab is a human monoclonal antibody that stimulates skeletal muscle growth by blocking the activin type II receptor (ActRII) and it is administered as a four-weekly intravenous infusion [96]
They also carry comparable side effect profiles, though some people tolerate one class better than the other
GLP-1 drug usage was associated with a reduced risk of just about everything bad: substance use and psychotic disorders, seizures, neuro-cognitive disorders (including Alzheimers disease and dementia), coagulation disorders [e.g., means clotting], cardio-metabolic disorders, infectious illnesses and several respiratory conditions. When I initially read this study in January, it seemed too good to be true
Instead of just describing how tired you feel, you can show them hard data, ensuring you get the right treatment plan
The primary endpoint will be percentage weight changes between the two drugs at week 72 (compared to baseline)